image
Healthcare - Biotechnology - NASDAQ - GB
$ 91.53
1.61 %
$ 7.78 B
Market Cap
-45.76
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one VRNA stock under the worst case scenario is HIDDEN Compared to the current market price of 91.5 USD, Verona Pharma plc is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one VRNA stock under the base case scenario is HIDDEN Compared to the current market price of 91.5 USD, Verona Pharma plc is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one VRNA stock under the best case scenario is HIDDEN Compared to the current market price of 91.5 USD, Verona Pharma plc is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart VRNA

image
$100.0$100.0$90.0$90.0$80.0$80.0$70.0$70.0$60.0$60.0$50.0$50.0$40.0$40.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
42.3 M REVENUE
0.00%
-155 M OPERATING INCOME
-127.96%
-173 M NET INCOME
-217.73%
-122 M OPERATING CASH FLOW
-143.33%
-580 K INVESTING CASH FLOW
0.00%
251 M FINANCING CASH FLOW
170.04%
76.3 M REVENUE
108.04%
-10.3 M OPERATING INCOME
43.74%
-16.4 M NET INCOME
51.57%
-11.6 M OPERATING CASH FLOW
59.91%
-535 K INVESTING CASH FLOW
-0.00%
13.5 M FINANCING CASH FLOW
-85.71%
Balance Sheet Verona Pharma plc
image
Current Assets 454 M
Cash & Short-Term Investments 400 M
Receivables 37.3 M
Other Current Assets 16.6 M
Non-Current Assets 20.7 M
Long-Term Investments 0
PP&E 3.15 M
Other Non-Current Assets 17.5 M
84.29 %7.86 %3.49 %3.69 %Total Assets$474.2m
Current Liabilities 42.7 M
Accounts Payable 11.3 M
Short-Term Debt 1.12 M
Other Current Liabilities 30.3 M
Non-Current Liabilities 227 M
Long-Term Debt 122 M
Other Non-Current Liabilities 105 M
4.18 %11.23 %45.08 %39.09 %Total Liabilities$269.7m
EFFICIENCY
Earnings Waterfall Verona Pharma plc
image
Revenue 42.3 M
Cost Of Revenue 2.58 M
Gross Profit 39.7 M
Operating Expenses 194 M
Operating Income -155 M
Other Expenses 18.8 M
Net Income -173 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)42m(3m)40m(194m)(155m)(19m)(173m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
93.89% GROSS MARGIN
93.89%
-365.73% OPERATING MARGIN
-365.73%
-410.18% NET MARGIN
-410.18%
-84.78% ROE
-84.78%
-36.57% ROA
-36.57%
-37.99% ROIC
-37.99%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Verona Pharma plc
image
00(20m)(20m)(40m)(40m)(60m)(60m)(80m)(80m)(100m)(100m)(120m)(120m)(140m)(140m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -173 M
Depreciation & Amortization 1.06 M
Capital Expenditures 0
Stock-Based Compensation 41.2 M
Change in Working Capital -5.74 M
Others 40.8 M
Free Cash Flow -123 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Verona Pharma plc
image
Wall Street analysts predict an average 1-year price target for VRNA of $87.7 , with forecasts ranging from a low of $37 to a high of $170 .
VRNA Lowest Price Target Wall Street Target
37 USD -59.58%
VRNA Average Price Target Wall Street Target
87.7 USD -4.22%
VRNA Highest Price Target Wall Street Target
170 USD 85.73%
Price
Max Price Target
Min Price Target
Average Price Target
180180160160140140120120100100808060604040202000Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 16
6. Ownership
Insider Ownership Verona Pharma plc
image
Sold
0-3 MONTHS
34.3 M USD 6
3-6 MONTHS
662 K USD 1
6-9 MONTHS
18.2 M USD 3
9-12 MONTHS
7.07 M USD 2
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
476 K USD 2
6-9 MONTHS
103 K USD 1
9-12 MONTHS
7. News
Wall Street Analysts Predict a 25.99% Upside in Verona Pharma (VRNA): Here's What You Should Know The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Verona Pharma (VRNA). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock. zacks.com - 2 weeks ago
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector. zacks.com - 2 weeks ago
Here's Why Momentum in Verona Pharma (VRNA) Should Keep going Verona Pharma (VRNA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen. zacks.com - 2 weeks ago
Verona Pharma: A Blockbuster Franchise In The Making Ohtuvayre's rapid US launch has driven explosive revenue growth, with Q1 2025 sales up 95% sequentially and refill rates signaling strong patient demand. With blockbuster potential, Wall Street projects Verona Pharma's sales to reach $1 billion by 2028, fueled by its safety profile and the unmet needs of those 398 million COPD sufferers worldwide. Global expansion, robust patent protection, and a growing pipeline position Verona for sustained high-margin growth and possible buyout interest. seekingalpha.com - 1 month ago
Investing $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today If you want to achieve significant gains in the stock market, you'll probably want to plan to hold on and remain invested for many years, or even decades. But in some cases, big payoffs can come much faster than that. fool.com - 1 month ago
Mizuho's Jared Holz details potential biotech, pharma acquisitions Mizuho's Jared Holz joins the 'Fast Money' team to discuss the potential impact of expiring patents within the biotech and pharmaceuticals industries. youtube.com - 1 month ago
Verona Pharma Announces June 2025 Investor Conference Participation LONDON and RALEIGH, N.C., May 21, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”) announces that senior management will participate in fireside chats at the following conferences in June 2025: globenewswire.com - 1 month ago
Verona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025 Analyses support Ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of PDE3 and PDE4 for a broad COPD population globenewswire.com - 2 months ago
Silencing The Doubters: Verona Pharma Could Be Sitting On A Blockbuster VRNA's COPD drug Ohtuvayre shows impressive Q1'25 net sales of $71.3M in just its third quarter of sales, all but confirming the blockbuster future of the drug. Ongoing R&D and trials, including a phase 3 trial in China that should readout in Q2'25, represent future clinical catalysts. A partnership in the UK or Europe is another potential near-term catalyst, although if the terms are not favorable, that could impact the performance of the stock. seekingalpha.com - 2 months ago
Verona Pharma plc (VRNA) Q1 2025 Earnings Call Transcript Verona Pharma plc (NASDAQ:VRNA ) Q1 2025 Earnings Conference Call April 29, 2025 9:00 AM ET Company Participants Victoria Stewart - Senior Director, Investor Relations and Communications David Zaccardelli - President and CEO Mark Hahn - CFO Christopher Martin - CCO Tara Rheault - Chief Development Officer Kathleen Rickard - Chief Medical Officer Conference Call Participants Andrew Tsai - Jefferies Yasmeen Rahimi - Piper Sandler Olivia Brayer - Cantor Fitzgerald Tara Bancroft - TD Cowen Tiago Fauth - Wells Fargo Thomas Shrader - BTIG Ram Selvaraju - HCW Sushila Hernandez - Van Lanschot Kempen Boobalan Pachaiyappan - ROTH Operator Welcome to Verona Pharma's First Quarter 2025 Financial Results and Operating Highlights Conference Call. At this time, all participants are in a listen-only mode. seekingalpha.com - 2 months ago
Verona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update Total net revenue of $76.3 million from Q1 2025 driven by Ohtuvayre ® net sales of $71.3 million (+95% vs Q4 2024) globenewswire.com - 2 months ago
Verona Pharma's Bull Case Holds, But Lifecycle Extension Is Critical Ohtuvayre's robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona's financial health is solid with $399.757 million in cash, providing a cash runway into 2028, despite a net loss of $33.8 million in Q4. Verona is extending Ohtuvayre's life cycle through new formulations and fixed-dose combinations, aiming for cash flow break-even with a quarterly run rate near $300 million. seekingalpha.com - 3 months ago
8. Profile Summary

Verona Pharma plc VRNA

image
COUNTRY GB
INDUSTRY Biotechnology
MARKET CAP $ 7.78 B
Dividend Yield 0.00%
Description Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Contact 3 More London Riverside, London, SE1 2RE https://www.veronapharma.com
IPO Date April 28, 2017
Employees 209
Officers Mr. Matthew Casbon Vice President of Sales, Marketing & Training Dr. Tara Rheault M.P.H., Ph.D. Chief Development Officer Mr. Christopher Martin Chief Commercial Officer Ms. Caroline Diaz Chief Regulatory Officer Mr. Mark W. Hahn Chief Financial Officer Mr. Andrew Fisher General Counsel Dr. Kathleen A. Rickard M.D. Chief Medical Officer Ms. Victoria Stewart Senior Director of Investor Relations & Communications Dr. David S. Zaccardelli Pharm.D. President, Chief Executive Officer & Executive Director Ms. Ostra Jewell Senior Vice President of Human Resources